The FDA’s Cardiovascular and Renal Drug Advisory Committee will vote tomorrow on whether or not the advantages of GSK’s daprodustat, an oral hypoxia-inducible prolyl hydroxylase issue inhibitor, outweigh its dangers for the remedy of anemia on account of persistent kidney illness (CKD) in grownup sufferers not on dialysis and on dialysis.
As soon as hailed as top-of-the-line medication within the UK drugmaker’s late-stage pipeline by former R&D chief Hal Barron, the FDA is now elevating critical questions on the advantages given among the potential dangers, noting that it “seeks the recommendation and proposals of the advisory committee on these safety issues,” including:
Preserve studying Endpoints with a free subscription
Unlock this story immediately and be part of over 152,000 biopharma professionals studying Endpoints day by day – and it is free.